These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 32862279

  • 1. High-dose versus low-dose intravenous immunoglobulin for treatment of children with Kawasaki disease weighing 25 kg or more.
    Suzuki T, Michihata N, Yoshikawa T, Hata T, Matsui H, Fushimi K, Yasunaga H.
    Eur J Pediatr; 2020 Dec; 179(12):1901-1907. PubMed ID: 32862279
    [Abstract] [Full Text] [Related]

  • 2. Sodium-containing versus sodium-trace preparations of IVIG for children with Kawasaki disease in the acute phase.
    Suzuki T, Michihata N, Aso S, Yoshikawa T, Saito K, Matsui H, Fushimi K, Yasunaga H.
    Eur J Pediatr; 2021 Nov; 180(11):3279-3286. PubMed ID: 33973071
    [Abstract] [Full Text] [Related]

  • 3. Low- versus high-concentration intravenous immunoglobulin for children with Kawasaki disease in the acute phase.
    Suzuki T, Michihata N, Yoshikawa T, Saito K, Matsui H, Fushimi K, Yasunaga H.
    Int J Rheum Dis; 2022 May; 25(5):576-583. PubMed ID: 35258165
    [Abstract] [Full Text] [Related]

  • 4. Association between intravenous immunoglobulin dose and outcomes in patients with acute Kawasaki disease.
    Michihata N, Suzuki T, Yoshikawa T, Saito K, Matsui H, Fushimi K, Yasunaga H.
    Eur J Pediatr; 2022 Oct; 181(10):3607-3615. PubMed ID: 35925450
    [Abstract] [Full Text] [Related]

  • 5. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
    Eleftheriou D, Moraes YC, Purvis C, Pursell M, Morillas MM, Kahn R, Mossberg M, Kucera F, Tulloh R, Standing JF, Swallow V, McCormack R, Herberg J, Levin M, Wan M, Klein N, Connon R, Walker AS, Brogan P.
    Trials; 2023 Jan 26; 24(1):60. PubMed ID: 36703139
    [Abstract] [Full Text] [Related]

  • 6. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
    Platt B, Belarski E, Manaloor J, Ofner S, Carroll AE, John CC, Wood JB.
    JAMA Netw Open; 2020 Jan 03; 3(1):e1918565. PubMed ID: 31899532
    [Abstract] [Full Text] [Related]

  • 7. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec 03; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 8. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH.
    PLoS One; 2015 Dec 03; 10(12):e0144603. PubMed ID: 26658843
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
    Lancet Child Adolesc Health; 2018 Dec 03; 2(12):855-862. PubMed ID: 30337183
    [Abstract] [Full Text] [Related]

  • 10. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM, Silverman ED, McCrindle BW, Yeung RS.
    J Pediatr; 2002 Apr 03; 140(4):450-5. PubMed ID: 12006960
    [Abstract] [Full Text] [Related]

  • 11. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
    J Med Assoc Thai; 2002 Nov 03; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [Abstract] [Full Text] [Related]

  • 12. Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE.
    Iio K, Morikawa Y, Miyata K, Kaneko T, Misawa M, Yamagishi H, Miura M.
    J Pediatr; 2022 Jan 03; 240():158-163.e4. PubMed ID: 34461064
    [Abstract] [Full Text] [Related]

  • 13. Effect of different doses of aspirin on the prognosis of Kawasaki disease.
    Wang J, Chen H, Shi H, Zhang X, Shao Y, Hang B, Xu Z, Rong X, Chu M, Qiu H.
    Pediatr Rheumatol Online J; 2020 Jun 11; 18(1):48. PubMed ID: 32527316
    [Abstract] [Full Text] [Related]

  • 14. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease.
    Chantasiriwan N, Silvilairat S, Makonkawkeyoon K, Pongprot Y, Sittiwangkul R.
    Paediatr Int Child Health; 2018 Aug 11; 38(3):209-212. PubMed ID: 29768976
    [Abstract] [Full Text] [Related]

  • 15. Association between aspirin dose and outcomes in patients with acute Kawasaki disease: a nationwide retrospective cohort study in Japan.
    Suzuki T, Michihata N, Hashimoto Y, Yoshikawa T, Saito K, Matsui H, Fushimi K, Yasunaga H.
    Eur J Pediatr; 2024 Jan 11; 183(1):415-424. PubMed ID: 37917176
    [Abstract] [Full Text] [Related]

  • 16. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
    Roberts SC, Jain S, Tremoulet AH, Kim KK, Burns JC, KIDCARE Multicenter Study Group, Anand V, Anderson M, Ang J, Ansusinha E, Arditi M, Ashouri N, Bartlett A, Chatterjee A, DeBiasi R, Dekker C, DeZure C, Didion L, Dominguez S, El Feghaly R, Erdem G, Halasa N, Harahsheh A, Jackson MA, Jaggi P, Jain S, Jone PN, Kaushik N, Kurio G, Lillian A, Lloyd D, Manaloor J, McNelis A, Michalik DE, Newburger J, Newcomer C, Perkins T, Portman M, Romero J, Ronis T, Rowley A, Schneider K, Schuster J, Tejtel SKS, Sharma K, Simonsen K, Szmuszkovicz J, Truong D, Wood J, Yeh S.
    Contemp Clin Trials; 2019 Apr 11; 79():98-103. PubMed ID: 30840903
    [Abstract] [Full Text] [Related]

  • 17. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
    Samadli S, Liu FF, Mammadov G, Wang JJ, Liu HH, Wu YF, Luo HH, Wu Y, Chen WX, Zhang DD, Wei W, Hu P.
    Pediatr Rheumatol Online J; 2019 Jul 31; 17(1):53. PubMed ID: 31366406
    [Abstract] [Full Text] [Related]

  • 18. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
    Lei WT, Chang LS, Zeng BY, Tu YK, Uehara R, Matsuoka YJ, Su KP, Lee PC, Cavalcante JL, Stubbs B, Lin PY, Wu YC, Hsu CW, Chen TY, Chen YW, Yeh PY, Sun CK, Tseng PT, Kao YH.
    EBioMedicine; 2022 Apr 31; 78():103946. PubMed ID: 35306339
    [Abstract] [Full Text] [Related]

  • 19. Analysis of Age, Sex, Lack of Response to Intravenous Immunoglobulin, and Development of Coronary Artery Abnormalities in Children With Kawasaki Disease in Japan.
    Takekoshi N, Kitano N, Takeuchi T, Suenaga T, Kakimoto N, Suzuki T, Kada TT, Shibuta S, Tachibana S, Murayama Y, Yamaga H, Suzuki H.
    JAMA Netw Open; 2022 Jun 01; 5(6):e2216642. PubMed ID: 35696166
    [Abstract] [Full Text] [Related]

  • 20. Relationship between post-IVIG IgG levels and clinical outcomes in Kawasaki disease patients: new insight into the mechanism of action of IVIG.
    Goto R, Inuzuka R, Shindo T, Namai Y, Oda Y, Harita Y, Oka A.
    Clin Rheumatol; 2020 Dec 01; 39(12):3747-3755. PubMed ID: 32458247
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.